Evidence map›Paper›PMID 38909345›Full record

ArticleMolecular genetics and genomics : MGG2024

Catalyzing precision: unraveling the diagnostic conundrum of tunisian familial hypophosphatasia case through integrative clinical and molecular approaches.

Yessine Amri, Rym Dabboubi, Monia Khemiri, Elham Jebabli, Sondess Hadj Fredj, Sarra Ben Ahmed, Yosr Jouini, Faida Ouali, Taieb Messaoud

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular genetics and genomics : MGG, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yessine AmriBiochemistry Laboratory (LR00SP03), Bechir Hamza Children's Hospital, Bab Saadoun Square, 1007, Tunis, Tunisia. amri.yessine@yahoo.com.ORCID http://orcid.org/0000-0003-0467-5016
Rym DabboubiBiochemistry Laboratory (LR00SP03), Bechir Hamza Children's Hospital, Bab Saadoun Square, 1007, Tunis, Tunisia.
Monia KhemiriPediatric Service, Bechir Hamza Children's Hospital, Tunis, Tunisia.
Elham JebabliPediatric Service, Bechir Hamza Children's Hospital, Tunis, Tunisia.
Sondess Hadj FredjBiochemistry Laboratory (LR00SP03), Bechir Hamza Children's Hospital, Bab Saadoun Square, 1007, Tunis, Tunisia.
Sarra Ben AhmedPediatric Service, Bechir Hamza Children's Hospital, Tunis, Tunisia.
Yosr JouiniBiochemistry Laboratory (LR00SP03), Bechir Hamza Children's Hospital, Bab Saadoun Square, 1007, Tunis, Tunisia.
Faida OualiBiochemistry Laboratory (LR00SP03), Bechir Hamza Children's Hospital, Bab Saadoun Square, 1007, Tunis, Tunisia.
Taieb MessaoudBiochemistry Laboratory (LR00SP03), Bechir Hamza Children's Hospital, Bab Saadoun Square, 1007, Tunis, Tunisia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Familial Hypophosphatasia presents a complex diagnostic challenge due to its wide-ranging clinical manifestations and genetic heterogeneity. This study aims to elucidate the molecular underpinnings of familial Hypophosphatasia within a Tunisian family harboring a rare c.896 T > C mutation in the ALPL gene, offering insights into genotype-phenotype correlations and potential therapeutic avenues. The study employs a comprehensive approach, integrating biochemical examination, genetic analysis, structural modeling, and functional insights to unravel the impact of this rare mutation. Genetic investigation revealed the presence of the p.Leu299Pro mutation within the ALPL gene in affected family members. This mutation is strategically positioned in proximity to both the catalytic site and the metal-binding domain, suggesting potential functional consequences. Homology modeling techniques were employed to predict the 3D structure of TNSALP, providing insights into the structural context of the mutation. Our findings suggest that the mutation may induce conformational changes in the vicinity of the catalytic site and metal-binding domain, potentially affecting substrate recognition and catalytic efficiency. Molecular dynamics simulations were instrumental in elucidating the dynamic behavior of the tissue-nonspecific alkaline phosphatase isozyme (TNSALP) in the presence of the p.Leu299Pro mutation. The simulations indicated alterations in structural flexibility near the mutation site, with potential ramifications for the enzyme's overall stability and function. These dynamic changes may influence the catalytic efficiency of TNSALP, shedding light on the molecular underpinnings of the observed clinical manifestations within the Tunisian family. The clinical presentation of affected individuals highlighted significant phenotypic heterogeneity, underscoring the complex genotype-phenotype correlations in familial Hypophosphatasia. Variability in age of onset, severity of symptoms, and radiographic features was observed, emphasizing the need for a nuanced understanding of the clinical spectrum associated with the p.Leu299Pro mutation. This study advances our understanding of familial Hypophosphatasia by delineating the molecular consequences of the p.Leu299Pro mutation in the ALPL gene. By integrating genetic, structural, and clinical analyses, we provide insights into disease pathogenesis and lay the groundwork for personalized therapeutic strategies tailored to specific genetic profiles. Our findings underscore the importance of comprehensive genetic and clinical evaluation in guiding precision medicine approaches for familial Hypophosphatasia.

Indexed as

Alkaline PhosphataseHypophosphatasiaPedigreeAdultCatalytic DomainFemaleGenetic Association StudiesHumansMaleMiddle AgedMolecular Dynamics SimulationMutationTunisiaAlkaline PhosphataseALPL protein, humanALPLHypophosphatasiaIn silico AnalysisMutations

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.